Investment Rating - The report maintains a "Buy" rating for several companies in the construction materials sector, including Puhua Co., China Jushi, Beixin Building Materials, and Yixing New Materials, while recommending "Hold" for Weixing New Materials [9]. Core Insights - The construction materials sector is experiencing a weak recovery, with cement prices fluctuating around the industry average without profitability [3][17]. - The demand for glass is showing seasonal improvement, but there are still supply-demand contradictions, with expectations of price fluctuations [4][34]. - The report emphasizes the positive impact of second-hand housing transactions and consumption stimulus policies on the demand for consumer building materials, recommending companies like Beixin Building Materials and Weixing New Materials [2][4]. Summary by Sections Cement Industry Tracking - As of April 30, 2025, the national cement price index is 379.72 yuan/ton, down 1.62% week-on-week, with a cement output of 3.545 million tons, up 0.7% [3][17]. - The cement industry is in a weak recovery phase, with construction demand being the main driver, but regional performance varies significantly [17]. Glass Industry Tracking - The average price of float glass is 1331.98 yuan/ton, with a slight increase of 0.02% week-on-week, and inventory levels are up year-on-year [4][34]. - Market demand remains moderate, and there is a lack of pre-holiday replenishment from downstream sectors [34]. Fiberglass Industry Tracking - The fiberglass market is experiencing weak demand, with prices under pressure due to increased supply and low operating rates in downstream processing plants [7]. - The report highlights the potential for price increases in high-end products due to strong demand [7]. Carbon Fiber Market Tracking - The carbon fiber market shows stable production levels, with a weekly output of 1679 tons and an operating rate of 60.62% [8]. - The report notes a gradual recovery in downstream demand, particularly in wind energy and hydrogen storage sectors [8]. Key Stocks - Recommended stocks include Puhua Co. (Buy), China Jushi (Buy), Beixin Building Materials (Buy), and Weixing New Materials (Hold) [9].

Investment Rating - The investment rating for the company is "Buy" [6] Core Views - The company's gene sequencing instrument business is experiencing steady growth, with significant progress in instrument installations. Despite short-term revenue pressure in Q1 2025 due to seasonal fluctuations, profit performance is driven by cost reduction and efficiency improvements. The acceleration of domestic substitution in 2025 is expected to lead to rapid growth in performance [2][4] Summary by Sections Financial Performance - In 2024, the company achieved revenue of 3.013 billion yuan, a year-on-year increase of 3.48%. The net profit attributable to the parent company was -601 million yuan, a year-on-year increase of 1.10%. The adjusted net profit was -653 million yuan, a year-on-year increase of 4.41%. In Q4 2024, revenue reached 1.143 billion yuan, a year-on-year increase of 61.64% [1] - For Q1 2025, the company reported revenue of 455 million yuan, a year-on-year decline of 14.26%. The net profit attributable to the parent company was -133 million yuan, a year-on-year increase of 33.67% [1][2] Business Segments - The gene sequencing instrument business generated revenue of 2.348 billion yuan in 2024, a year-on-year increase of 2.47%. Instrument revenue was 960 million yuan (up 6.92%), and reagent revenue was 1.373 billion yuan (up 1.43%). The laboratory automation business generated 209 million yuan (down 4.09%) [2] - In Q1 2025, the company launched several new products, including the DNBSEQ-AIO library preparation sequencer and the DNBSEQ-E25 Flash sequencer, which are expected to strengthen future growth [4] International Expansion - The company has established a global presence across over 110 countries, with nine R&D centers, seven production bases, and nine international spare parts warehouses. In 2024, overseas revenue from the gene sequencing instrument business was 741 million yuan, a year-on-year decrease of 12.66% [3] - The company has made significant strides in localizing its operations, with the U.S. factory now operational and producing the DNBSEQ-G99 sequencer [3] Future Projections - Revenue projections for 2025-2027 are 3.736 billion yuan, 4.306 billion yuan, and 4.959 billion yuan, representing year-on-year growth rates of 24.0%, 15.3%, and 15.2%, respectively. The net profit attributable to the parent company is expected to improve significantly, reaching -57 million yuan in 2025 and 144 million yuan in 2026 [4][5]

证券研究报告 | 年报点评报告 gszqdatemark 2025 05 05 年 月 日 迈瑞医疗（300760.SZ） 政策扰动下 25Q1 短期承压，招标恢复趋势下看好业绩逐季改善 迈瑞医疗发布 2024 年度报告。2024 年公司实现营业收入 367.26 亿元，同比增长 5.14%；归母净利润 116.68 亿元，同比增长 0.74%；扣非后归母净利润 114.42 亿元， 同比增长 0.07%。分季度看，2024Q4 实现营业收入 72.41 亿元，同比下滑 5.08%；归 母净利润 10.31 亿元，同比下滑 40.99%；扣非后归母净利润 10.05 亿元，同比下滑 42.49%。 迈瑞医疗发布 2025 年度一季报。2025Q1 公司实现营业收入 82.37 亿元，同比下滑 12.12%；归母净利润 26.29 亿元，同比下滑 16.81%；扣非后归母净利润 25.31 亿元， 同比下滑 16.68%。 观点：2024 年体外诊断业务稳健增长，高端超声 A20 放量驱动医学影像板块增长， 种子业务蓄势待发，多产品线各放异彩。2025Q1 业绩阶段性承压，主要系国内政策 扰动及海外同期高基数影 ...

海上风电迎来密集开工，英联股份持续拓宽复合集流体合作版图 光伏：硅料价格继续下跌，成交价环比下降 2.6~2.7%。根据硅料分会报道， 随着 5、6 月下游排产开始下调，本周硅料价格继续下跌。n 型复投料成交价 格区间为 3.70-4.50 万元/吨，成交均价为 3.92 万元/吨，环比下降 2.73%；n 型颗粒硅成交价格区间为 3.60-3.80 万元/吨，成交均价为 3.70 万元/吨，环比 下降 2.63%；p 型多晶硅成交价格区间为 3.10-3.50 万元/吨，成交均价为 3.23 万元/吨，环比下降 2.12%。目前预计 5 月硅料排产在 10 万吨左右，关注后 续降排产情况。核心关注两大方向：1）供给侧偏刚性、后续需求复苏后价格 弹性更大的硅料和玻璃，核心关注协鑫科技、通威股份、福莱特等。2）新技 术背景下带来的中长期成长性机会，核心关注爱旭股份、聚和材料等。 风电&电网：海上风电迎来密集开工。包括华能山东半岛北 L 场址海上风电项 目、浙江舟山普陀 2#海上风电场项目开工、瑞安 2 号 600MW。风电板块， 关注海缆：东方电缆、中天科技、亨通光电、起帆电缆，桩基：天顺风能、海 力风电、大金 ...

增持（维持） 证券研究报告 | 行业周报 gszqdatemark 2025 05 05 年 月 日 钢铁 约束供给扩大消费 行情回顾（4.28-4.30）： 中信钢铁指数报收 1,528.72 点，下跌 0.52%，跑输沪深 300 指数 0.09pct，位列 30 个中信 一级板块涨跌幅榜第 16 位。 重点领域分析： 投资策略：受假期影响本周交易日有限，海外交易市场贵金属价格出现一定的调整，黑色商 品则依然震荡。根据财联社，宝钢回应近期钢铁市场传闻行业将限产 5000 万吨以应对近年 来市场供需结构的变化是大概率事件，但随后黑色商品价格表现平淡，行业内对今年限产落 实疑虑较大。由于过去在执行中存在一定的落实障碍，加之今年的监督和奖惩还缺少更多的 细节，市场抱有一定的疑虑是正常的。中国"内卷"很大原因是由于地方政府尤其青睐重资 产的制造业，一是因为投资规模大，对 GDP 拉动作用明显；二是因为增值税在生产环节征 收，跟生产规模直接挂钩；三是因为制造业不仅可以吸纳从农业部门转移出的低技能劳动力， 也可以带动第三产业发展，增加相关税收。因为绝大多数税收征收自企业，且多在生产环节 征收，所以过去地方政府重视企业 ...

Investment Rating - The investment rating for the company is "Buy" [6] Core Views - The company's performance in 2024 faced temporary pressure due to domestic industry restructuring and equipment update cycles, while overseas markets experienced rapid growth. The first quarter of 2025 showed positive year-on-year growth in both revenue and profit, indicating a gradual release of equipment update demand. The company achieved breakthroughs in high-end markets and penetration in emerging regions, enhancing its global presence as a leading domestic medical imaging company [2][3] Financial Performance Summary - In 2024, the company reported revenue of 10.3 billion yuan, a year-on-year decline of 9.73%, and a net profit attributable to shareholders of 1.262 billion yuan, down 36.09%. The first quarter of 2025 saw revenue of 2.478 billion yuan, an increase of 5.42%, and a net profit of 370 million yuan, up 1.87% [1][5] - The service business showed strong performance in 2024, with revenue of 1.356 billion yuan, a year-on-year increase of 26.80%, and a gross margin of 63.43%. In contrast, the equipment business faced challenges, with revenue of 8.445 billion yuan, a decline of 14.93% [2][3] - The company's overseas revenue reached 2.22 billion yuan in 2024, a year-on-year increase of 33.81%, while domestic revenue was 7.664 billion yuan, down 19.43% [3] Product and Market Development - The company has launched over 140 innovative products by the end of 2024, with significant certifications including 46 CE MDR and 49 FDA approvals. Notable products include advanced MRI and CT systems, enhancing the company's product portfolio [4] - The company has expanded its overseas business to over 85 countries and regions, achieving significant market penetration in North America and Europe, and making strides in emerging markets such as India, Turkey, Mexico, and Brazil [3][4] Future Projections - Revenue projections for 2025 to 2027 are estimated at 12.354 billion yuan, 15.130 billion yuan, and 18.326 billion yuan, respectively, with year-on-year growth rates of 19.9%, 22.5%, and 21.1%. Net profit projections for the same period are 1.803 billion yuan, 2.245 billion yuan, and 2.746 billion yuan, with growth rates of 42.8%, 24.6%, and 22.3% [4][5]

Investment Rating - The investment rating for the company is "Buy" [7] Core Views - The company has shown strong performance in overseas markets, with a revenue increase of 27.67% in 2024, while domestic revenue grew by 9.32% despite pricing pressures from procurement policies [2][3] - The company is expanding its high-end product offerings and increasing its market share in both domestic and international markets, with significant progress in the installation of high-end models [4] - The company is expected to achieve revenue growth of 13.7%, 16.5%, and 17.8% for the years 2025, 2026, and 2027 respectively, with net profit growth of 12.8%, 17.6%, and 18.4% during the same period [4] Summary by Sections Financial Performance - In 2024, the company achieved a total revenue of 45.35 billion yuan, a year-on-year increase of 15.41%, and a net profit of 18.28 billion yuan, up 10.57% [1] - The gross margin for 2024 was 72.07%, with a slight decrease of 0.89 percentage points compared to the previous year [2] - For Q1 2025, the company reported revenue of 11.25 billion yuan, a 10.12% increase year-on-year, and a net profit of 4.38 billion yuan, up 2.65% [1][3] Market Segmentation - The overseas market contributed 16.84 billion yuan in revenue in 2024, reflecting a growth of 27.67%, driven by increased installation of instruments [2] - The domestic market generated 28.43 billion yuan in revenue, with a growth of 9.32%, supported by expanding coverage in tertiary hospitals [2][4] Product Development - The company installed 1,641 units of chemical luminescence instruments in the domestic market, with large machines accounting for 74.65% of installations [4] - In the overseas market, the company installed 4,017 units, with high-end models making up 67.16% of the total installations [4] Future Projections - Revenue projections for 2025, 2026, and 2027 are 51.58 billion yuan, 60.07 billion yuan, and 70.75 billion yuan respectively, with corresponding net profits of 20.63 billion yuan, 24.27 billion yuan, and 28.74 billion yuan [4][6]

电力设备 海上风电迎来密集开工，英联股份持续拓宽复合集流体合作版图 光伏：硅料价格继续下跌，成交价环比下降 2.6~2.7%。根据硅料分会报道， 随着 5、6 月下游排产开始下调，本周硅料价格继续下跌。n 型复投料成交价 格区间为 3.70-4.50 万元/吨，成交均价为 3.92 万元/吨，环比下降 2.73%；n 型颗粒硅成交价格区间为 3.60-3.80 万元/吨，成交均价为 3.70 万元/吨，环比 下降 2.63%；p 型多晶硅成交价格区间为 3.10-3.50 万元/吨，成交均价为 3.23 万元/吨，环比下降 2.12%。目前预计 5 月硅料排产在 10 万吨左右，关注后 续降排产情况。核心关注两大方向：1）供给侧偏刚性、后续需求复苏后价格 弹性更大的硅料和玻璃，核心关注协鑫科技、通威股份、福莱特等。2）新技 术背景下带来的中长期成长性机会，核心关注爱旭股份、聚和材料等。 风电&电网：海上风电迎来密集开工。包括华能山东半岛北 L 场址海上风电项 目、浙江舟山普陀 2#海上风电场项目开工、瑞安 2 号 600MW。风电板块， 关注海缆：东方电缆、中天科技、亨通光电、起帆电缆，桩基：天顺风能、海 力 ...

证券研究报告 | 行业周报 gszqdatemark 2025 05 05 年 月 日 通信 从海外云厂商财报看"算力信心" AI 发展的宏大叙事并未发生改变，其投资的持续性与确定性已在 CSP 巨 头财报中得到进一步印证。本周微软、Meta、亚马逊陆续发布财报，为 市场观察其在 AI 领域投资及进展提供新窗口。从下游应用看，AI 推动各 大企业相关业务增速明显，其业绩正逐步兑现；从投资侧看，Capex 仍 彰显对 AI 基础设施建设的强劲需求，AI 技术已从底层算力渗透到垂类应 用，商业化进程持续加速。 AI 对业绩贡献逐步兑现，Capex 持续印证高景气度。本周北美各 CSP 巨 头陆续公布财报，尽管关税政策导致宏观前景不明，但三家科技巨头财报 数据均给出超出市场预期的营收和净利润，且均表示 AI 对业绩增长起到 重要作用，未来仍将保持、甚至部分继续上调高水平资本支出： 我们认为，尽管受关税扰动市场仍存担忧，但 AI 本身需求并未变化。目 前正通过"资本开支扩张-商业化落地-业绩兑现"的正向循环持续发展， 未来伴随大模型技术突破、行业应用场景的持续拓展与业绩的逐步兑现， 算力产业链仍将保持高景气度，建议关 ...

证券研究报告 | 行业周报 gszqdatemark 2025 05 05 年 月 日 钢铁 约束供给扩大消费 行情回顾（4.28-4.30）： 中信钢铁指数报收 1,528.72 点，下跌 0.52%，跑输沪深 300 指数 0.09pct，位列 30 个中信 一级板块涨跌幅榜第 16 位。 重点领域分析： 投资策略：受假期影响本周交易日有限，海外交易市场贵金属价格出现一定的调整，黑色商 品则依然震荡。根据财联社，宝钢回应近期钢铁市场传闻行业将限产 5000 万吨以应对近年 来市场供需结构的变化是大概率事件，但随后黑色商品价格表现平淡，行业内对今年限产落 实疑虑较大。由于过去在执行中存在一定的落实障碍，加之今年的监督和奖惩还缺少更多的 细节，市场抱有一定的疑虑是正常的。中国"内卷"很大原因是由于地方政府尤其青睐重资 产的制造业，一是因为投资规模大，对 GDP 拉动作用明显；二是因为增值税在生产环节征 收，跟生产规模直接挂钩；三是因为制造业不仅可以吸纳从农业部门转移出的低技能劳动力， 也可以带动第三产业发展，增加相关税收。因为绝大多数税收征收自企业，且多在生产环节 征收，所以过去地方政府重视企业而相对轻视民生 ...